476 results about "Homeostasis" patented technology

The invention provides a compound with a structure as shown in a formula (I). The compound can be used as a polyphenol organic ligand to be self-assembled with metal ions to form metal polyphenol nanoparticles. The nano-particles have a bone targeting effect, are safe, effective, stable and uniform, can realize whole-body transfer, can be degraded in a bone pathology microenvironment, have regulation and control effects on bone resorption and bone formation, can cooperatively regulate and control bone balance, and have a great application prospect in the field of bone diseases such as osteoporosis. # imgabs0 #

The invention belongs to the technical field of food functional ingredient nutriology research, and discloses application of narirutin in improving the intestinal flora homeostasis of food allergy organisms. The narirutin can adjust the relative abundance value of certain intestinal flora by adjusting the diversity of the intestinal flora of a food allergy body, improve the relative abundance of beneficial bacteria and harmful bacteria, and can influence the metabolism of short-chain fatty acid of the intestinal flora of the food allergy body, so that the food allergy body is improved. Further, the application of the narirutin in improving the intestinal flora homeostasis of food allergy organisms is realized. The application of narirutin in the research fields of nutriology, biology and pharmacology is expanded.

The invention discloses a triggering probiotic-drug conjugate and a preparation method and application thereof, and belongs to the technical field of oral drug delivery systems, the triggering probiotic-drug conjugate comprises probiotics, an adhesive inner layer formed by coordination of tannic acid and Fe < 3 + >, and an outer layer formed by pterostilbene-phospholipid bridged by ROS-responsive thioether bonds and cholesterol; the inner layer coats the surfaces of the probiotics through coordination, and the outer layer coats the outer part of the inner layer through self-assembly. An outer lipid layer is decomposed under high-concentration ROS in an inflammation colon area, and probiotics coated with pterostilbene and a tannic acid layer are released. Pterostilbene relieves inflammation and rebuilds a pathological microenvironment, and catechol groups in a tannic acid layer and the surface of the intestinal tract generate multiple interactions to promote planting of probiotics. In UC mouse models, the conjugates exhibit enhanced therapeutic effects by inhibiting inflammation, restoring intestinal barrier function, and improving intestinal microbiota homeostasis. The invention has important transformation potential in clinical application of gastrointestinal diseases.

The invention discloses a BRIX1 inhibitor and application of the BRIX1 inhibitor in tumor resistance, and particularly discloses a nucleoprotein BRIX1 which is a key regulatory factor of a steady state between ribosome biogenesis and p53 activation. Research results show that inhibition of BRIX1 can induce nucleolus stress to activate p53, so that growth of tumors is inhibited. Besides, the engineered exosome is constructed, the surface of the engineered exosome is decorated with iRGD, and the engineered exosome is loaded with siRNA with BRIX1 specificity and is used for treating cancers.

The invention provides a traditional Chinese medicine monomer composition for preventing and / or treating pulmonary fibrosis as well as a preparation and application thereof, and belongs to the technical field of biological medicines. The traditional Chinese medicine monomer composition comprises the following components: schisandrin B and platycodin D. The traditional Chinese medicine monomer composition can obviously reduce fiber cell and collagen deposition, relieve inflammatory cell infiltration, obviously reduce the lung coefficient, alveolar inflammation score and pulmonary fibrosis score, and recover the normal physiological structure of rat lung tissue. The traditional Chinese medicine monomer composition provided by the invention can reduce the expression contents of KL-6, MMP-7, SP-A and SP-D and lung tissue HYP in serum, and has the effects of relieving collagen deposition and alveolar epithelium injury, maintaining alveolar homeostasis and improving pulmonary fibrosis. Therefore, the traditional Chinese medicine composition provided by the invention is definite and reliable in curative effect and can be used for preparing medicines for preventing and / or treating pulmonary fibrosis.

The invention discloses application of a bifidobacterium animalis subspecies F1-3-2 in preparation of a medicine for preventing or treating sarcopenia, belongs to the technical field of microorganism application, and provides application of the bifidobacterium animalis subspecies F1-3-2 in preparation of the medicine for preventing or treating sarcopenia. The invention relates to an application of bifidobacterium animalis subspecies F1-3-2 in preparation of a medicine for correcting intestinal flora imbalance caused by sarcopenia. The invention finds that the bifidobacterium animalis subspecies F1-3-2 can effectively improve the skeletal muscle quality of mice with sarcopenia, improve the condition of tension reduction, improve the level of serum markers in sarcopenia, regulate the homeostasis of intestinal flora so as to relieve muscular atrophy, prepare freeze-dried bacterial powder and enrich products for improving sarcopenia.

The invention discloses a composition for regulating sleep rhythm homeostasis as well as a preparation method and application thereof. The composition for regulating the sleep rhythm homeostasis is prepared from the following components in percentage by weight: 5 to 18 percent of polydextrose, 9 to 15 percent of galactooligosaccharide, 1 to 10 percent of inulin, 0.4 to 2 percent of gamma-aminobutyric acid, 0.8 to 2.2 percent of L-theanine, 0.1 to 3.5 percent of magnesium citrate, 2 to 21 percent of semen ziziphi spinosae extract, 1 to 10 percent of poria cocos extract, 0.5 to 2 percent of pericarpium citri reticulatae extract, 0.3 to 1 percent of liquorice root extract and 15 to 40 percent of maltodextrin. 5-18% of coconut oil powder MCTs, and 0.5-2% of a lily extract. According to the application, a magnesium MCTs shell-core structure is delivered by maltodextrin to form a mitochondrial piezoelectric engine so as to improve prebiotics, promote flora metabolism efficiency and energy supply feedback, activate intestinal pheochromophilic cells and improve SLC6A4 gene expression so as to improve synthesis of 5-hydroxytryptamine in the brain and activate GABA energy neurons; meanwhile, through the spina date seed and poria cocos quantum dots and a pericarpium citri reticulatae and liquorice pi-pi stacking network, the blood-brain barrier penetration rate is greatly increased, and hypothalamic CRH release is adjusted.

The growth factor profile, connective tissue matrix constituents, and immunoprivileged status of urodele extracellular matrix (ECM) and accompanying cutaneous tissue, plus the presence of antimicrobial peptides there, render urodele-derived tissue an ideal source for biological scaffolds for xenotransplantation. In particular, a biological scaffold biomaterial can be obtained by a process that entails (A) obtaining a tissue sample from a urodele, where the tissue comprises ECM, inclusive of the basement membrane, and (B) subjecting the tissue sample to a decellularization process that maintains the structural and functional integrity of the extracellular matrix, by virtue of retaining its fibrous and on-fibrous proteins, glycoaminoglycans (GAGs) and proteoglycans, while removing sufficient cellular components of the sample to reduce or eliminate antigenicity and immunogenicity for xenograft purposes. The resultant urodele-derived biomaterial can be used to enhance restoration of skin homeostasis, to reduce the severity, durations and associated damage caused by post-surgical inflammation, and to promote progression of natural healing and regeneration processes. In addition, the biomaterial promotes the formation of remodeled tissue that is comparable in quality, function, and compliance to undamaged human tissue.

The invention provides a method for verifying the protective effect of a semen descurainiae water extract on myocardial injury, so as to evaluate the pharmacodynamic effect of the semen descurainiae water extract on heart failure induced by three inducements of acute ischemia-reperfusion injury, pathological cell hypertrophy and chronic hypoxia. The method comprises the following steps: respectively constructing a hiPSC-CMs-based myocardial acute ischemia reperfusion injury model, a pathological fat myocardial injury model and a chronic hypoxic myocardial injury model, and after the myocardial injury models are established, adding a descurainia seed aqueous extract and a positive control drug for intervention. And detecting corresponding indexes to verify the effect of the descurainia seed water extract on three types of heart failure. The result shows that the semen descurainiae water extract can generate a treatment effect on myocardial injury caused by chronic hypoxia by regulating and controlling the steady state of energy metabolism, inhibiting oxidative stress cascade reaction and other mechanisms.

The invention belongs to the technical field of biological medicine, and relates to application of a clerodendranthus spicatus tea bag in regulating intestinal excretion and reducing uric acid. One of the purposes of the invention is to provide the application of the clerodendranthus spicatus teabag in regulating intestinal tracts to reduce uric acid According to a preferred embodiment, the clerodendranthus spicatus teabag regulates ATP binding cassette transporter G2 and inhibits uricase activity. The invention provides the application of the clerodendranthus spicatus teabag in regulating the intestinal microbial environment and reducing uric acid, and the clerodendranthus spicatus teabag has remarkable beneficial effects. The clerodendranthus spicatus teabag can effectively regulate the structure and the function of intestinal microflora, especially the enrichment amount of characteristic bacteria Muriaculum in the intestinal tract, further strengthens the probiotic activity of the intestinal flora, and is helpful for maintaining the steady state of uric acid in the body. The multi-way synergistic effect not only provides an innovative strategy for preventing and treating hyperuricemia and related metabolic diseases, but also avoids side effects possibly brought by traditional medicines, and shows good application prospects and clinical values.

The invention discloses a preparation method and application of a multifunctional layered nanosheet. The biomimetic hydrogel is prepared through a hydrothermal method, folic acid (FA) is modified on the surface of the biomimetic hydrogel, and the biomimetic hydrogel has the capacity of targeted recognition of pro-inflammatory phenotype macrophages, has the biomimetic activity of multiple enzymes such as superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPx) and can effectively remove ROS; meanwhile, a succinate dehydrogenase (SDH) inhibitor dimethylmalonic acid (DMM) is loaded in an intercalation mode of the nano material, SDH activity is inhibited in a slow release mode, ROS outbreak caused by mitochondrial reverse electron transfer (RET) is blocked from the source, then a mitochondrial autophagy pathway mediated by BNIP3-LC3B is started, and dynamic and steady state recovery of mitochondria is achieved. The system finally realizes macrophage mitochondrial function reconstruction, oxidation environment improvement and transfer of healthy mitochondria to osteoblasts, so that the osteogenic differentiation capability is recovered, and the effect of treating osteoporosis is achieved.

The application provides application of a TT2-SCT1 / SCT2-WR2 regulation channel in plant heat stress tolerance. The application first discloses a new signal channel involved in plant heat tolerance: a TT2-SCT1 / SCT2-WR2 signal channel; wherein, TT2 is a negative regulation factor for regulating the heat tolerance of plants or protecting (maintaining) the yield of plants in Gramineae under high temperature, SCT1 / SCT2 are also negative regulation factors for regulating the heat tolerance of plants or protecting (maintaining) the yield of plants in Gramineae under high temperature, and WR2 is a positive regulation factor for playing a role, which is beneficial to maintaining the homeostasis in plants. The application has important theoretical significance for genetic improvement of plant traits.

The invention relates to the technical field of probiotics and application thereof, in particular to a plant lactobacillus ZKAW02 strain, a fungicide and application of the fungicide. The invention relates to a plant lactobacillus ZKAW02 strain, which is classified and named as plant lactobacillus, the plant lactobacillus ZKAW02 strain is preserved in Guangdong Province Microbial Culture Collection Center on September 27, 2024, and the preservation number is GDMCC No: 65219. The invention further discloses a preparation method of the plant lactobacillus ZKAW02 strain. The plant lactobacillus ZKAW02 strain has the advantages that the plant lactobacillus ZKAW02 strain is named as plant lactobacillus, and the plant lactobacillus ZKAW02 strain is preserved in Guangdong Province Microbial Culture Collection Center on September 27, 2024. The lactobacillus plantarum ZKAW02 has the effects of remarkably reducing the cholesterol level, remarkably regulating the blood fat level of the liver and excrement and remarkably increasing the short-chain fatty acid level in the excrement of a high-fat rat, so that the expression level of lipid metabolism related signal channel genes is regulated, the intestinal flora homeostasis is regulated, the liver tissue damage is repaired, and the anti-tumor effect is achieved. The effects of regulating lipid metabolism and intestinal health are achieved.

The invention discloses application of an Hspa5 inhibitor in preparation of a medicine for preventing or treating anxiety disorder. An anxiety mouse model is constructed through chronic constraint stress (CRS), and in combination with medial amygdala kernel (MeA) transcriptome sequencing and qPCR verification, it is found that the endoplasmic reticulum molecular chaperone Hspa5 is remarkably up-regulated in the anxiety state. Furthermore, an Hspa5 specific inhibitor HA15 is locally injected into a MeA brain region, so that the anxiety-like behavior induced by the CRS is remarkably improved, and the exploration time of an open field experiment central region, the exploration time of an open arm of an elevated cross labyrinth and the exploration time of a bright box of a bright-dark box experiment are prolonged. The invention discloses the function of Hspa5 as a novel anti-anxiety target for the first time, and provides a direct experimental basis and a transformation direction for developing a novel anti-anxiety drug which is non-monoamine and targets an endoplasmic reticulum homeostasis.

The present invention provides an agent capable of modulating variable splicing in the intron of the SLC20A2 gene, and its use for modulating the expression of functional PiT2 protein to prevent and / or treat disease. The invention further provides a brain calcification model based on variable splicing in the intron of the human SLC20A2 gene, a preparation method of the brain calcification model, and application of the model to indication and analysis of the incidence stage of brain calcification, or to a model for researching phosphorus homeostasis imbalance in brain or a target of brain calcification, or to screening of drugs.

The invention discloses a composite bone graft material based on bletilla striata polysaccharide and autologous tooth bone meal as well as a preparation method and application of the composite bone graft material. The preparation method comprises the following steps: preparing bletilla striata polysaccharide, namely BSP, from bletilla striata; the method comprises the following steps: pretreating extracted teeth, and crushing to obtain autologous tooth bone powder, namely AutoBT; dissolving the BSP in water, and uniformly stirring to obtain a BSP solution; the AutoBT is poured into the BSP solution, and after standing and stirring, an AutoBT solution loaded with BSP is obtained; and carrying out vacuum drying on the AutoBT solution loaded with the BSP, and carrying out ultraviolet sterilization to obtain the composite bone graft material. The material can be applied to repairing of oral cavity bone defects, bletilla striata polysaccharide has the effects of resisting inflammation, inhibiting bacteria, promoting osteogenesis and inhibiting osteoclast, the bone steady state unbalance state in the periodontitis environment is effectively reversed, meanwhile, autologous tooth bone powder accelerates bone tissue regeneration and integration by means of the natural bionic structure and high porosity of the autologous tooth bone powder, and the bone tissue regeneration effect is improved. The risks of postoperative infection and immunological rejection are reduced.

The invention discloses an immune homeostasis supporting agent based on mushroom active ingredients and fungal polysaccharides, and relates to the technical field of biological medicine and functional foods.The method comprises the following steps that a pleurotus citrinopileatus homeostasis adjusting extracting solution is prepared, specifically, pleurotus citrinopileatus sporocarp powder is extracted with water at the temperature of 80-100 DEG C according to the material-liquid ratio of 1 g: 35-45 mL, and a pleurotus citrinopileatus homeostasis adjusting extracting solution is obtained; the leaching time is 30-60 minutes, so as to obtain pleurotus citrinopileatus leaching liquor; the pleurotus citrinopileatus leach liquor is sequentially subjected to vacuum concentration and decoloration treatment, a pleurotus citrinopileatus steady-state regulation extracting solution with the concentration being 0.5-2 g / mL is obtained, and the pleurotus citrinopileatus steady-state regulation extracting solution shows the two-way regulation characteristic in an experimental model, so that the immunologic function index in the immunosuppression state can be improved, the excessive immune response can be relieved, and the immunologic function index of the pleurotus citrinopileatus can be improved. Therefore, the immune system is guided and maintained in a balanced and stable optimal state.

The invention relates to the technical field of drugs for treating intervertebral disc degeneration, in particular to application of a TFEB agonist in preparation of drugs for treating intervertebral disc degeneration. The key regulation effect of the transcription factor TFEB in intervertebral disc degeneration is provided. Researches on intervertebral disc specimens with different degeneration degrees and rat and mouse models find that the expression level of TFEB is obviously reduced along with the increase of the degeneration degree of the intervertebral disc. In addition, abnormal mechanical stresses and other stimuli result in a significant reduction in TFEB expression in nucleus pulposus cells, accompanied by disorders of lipid metabolism. Therefore, the TFEB plays a key role in maintaining the lipid metabolism homeostasis of the nucleus pulposus cells. The deletion of TFEB aggravates abnormal mechanical load and age-related disc degeneration and leads to a disorder in the biological behavior of nucleus pulposus cells. On the contrary, overexpression of TFEB can significantly relieve the degeneration phenomenon, and normal functions and lipid metabolism balance of nucleus pulposus cells are recovered.

The invention belongs to the technical field of biological medicine manufacturing, and particularly provides a preparation method of an engineered exosome capable of loading mitochondria for treating pulmonary fibrosis and the engineered exosome. The method comprises the following steps: constructing fusion plasmids for expressing mitochondrial targeting peptide fragment-therapeutic protein genes, dissolving the fusion plasmids in non-enzyme ultrapure water, adding the fusion plasmids into a lipid nano-preparation, and fully mixing to obtain a nano-preparation containing the therapeutic protein genes; the nano preparation is delivered into alveolar epithelial cells and is efficiently transfected, so that the homeostatic balance of the injured alveolar epithelial cells in the development of pulmonary fibrosis is effectively regulated and controlled, the secretion of an exosome with a therapeutic effect is promoted, and the engineered exosome is further obtained through mannose modification. The exosome can effectively load mitochondria and sequentially and accurately target macrophage mitochondria on the basis of a mannose target head and a mitochondrial targeting peptide fragment, so that macrophage mitochondrial homeostatic balance is effectively regulated and controlled, the purpose of reverse treatment of pulmonary fibrosis is achieved, and the exosome has high clinical application value.

The invention belongs to the technical field of biological medicines, and discloses a B cell and cartilage cell senescence targeting osteoarthritis treatment medicine. The invention provides an application of an anti-MIF antibody or an antigen binding fragment thereof as a B cell targeting immunomodulator in osteoarthritis treatment drugs, the anti-MIF antibody or the antigen binding fragment thereof regulates and controls an MIF / HMGB1 / MMP13 signal axis through a neutralization effect with MIF, so that the MIF and B cells are significantly co-localized, expression of HMGB1 in the B cells is promoted, and the osteoarthritis treatment effect is improved. The senescence of B cells is reduced and the B cells are promoted to regulate or repair phenotype transformation so as to destroy chronic inflammatory circulation and diffusion of pathogenic plasma cells, and the expression of MMP13 in joint tissues is reduced so as to maintain the steady state of cartilage tissues; the preparation method has an excellent application prospect in preparation of an OA intra-articular injection drug which realizes rapid anti-inflammatory and long-term cartilage protection effects and can realize a lasting curative effect through low-frequency drug delivery.

The generation of complex organ tissues from human embryonic and pluripotent stem cells (PSCs) remains a major challenge for translational studies. It is shown that PSCs can be directed to differentiate into intestinal tissue in vitro by modulating the combinatorial activities of several signaling pathways in a step-wise fashion, effectively recapitulating in vivo fetal intestinal development. The resulting intestinal “organoids” were three-dimensional structures consisting of a polarized, columnar epithelium surrounded by mesenchyme that included a smooth muscle-like layer. The epithelium was patterned into crypt-like SOX9-positive proliferative zones and villus-like structures with all of the major functional cell types of the intestine. The culture system is used to demonstrate that expression of NEUROG3, a pro-endocrine transcription factor mutated in enteric anendocrinosis is sufficient to promote differentiation towards the enteroendocrine cell lineage. In conclusion, PSC-derived human intestinal tissue should allow for unprecedented studies of human intestinal development, homeostasis and disease.

The present invention relates to the cosmetic field, in particular to cosmetic agents able to restore or maintain cutaneous homeostasis. More precisely, the invention relates to the cosmetic use of an agent able to increase synaptopodin expression in keratinocytes for improving, restoring or maintaining cutaneous homeostasis, preferably epidermal homeostasis, in a healthy skin. The invention also relates to cosmetic compositions comprising the same as well as cosmetic methods using the same.

The present disclosure relates to a functionalized statistic chitosan of weight average molecular mass between 100 kDa and 1000 kDa and of formula (I):whereineach Rc is independently a moiety comprising a chelating agent,each Z is independently a linker which is a single bond or a hydrocarbon chain containing between 1 and 12 carbon atoms, said hydrocarbon chain is linear or branched and optionally contains one or more unsaturations and one or more heteroatoms,x is between 0.005 and 0.7, preferably between 0.05 and 0.7,y is between 0.01 and 0.7, preferably between 0.05 and 0.2,the ratio y / x being greater than or equal to 0.05, preferably greater than or equal to 0.15, andthe sum x+y being greater than or equal to 0.15, for use in the treatment of diseases characterized by local inflammation induced by and / or inducing a deregulation of metal homeostasis and increased oxidative stress, in a subject in need thereof.

The invention discloses a composition, a medicine and application of the medicine in tumor treatment, and relates to the technical field of tumor treatment. The composition comprises a methacrylic acid-ethyl acrylate copolymer and photosynthetic bacteria, wherein the photosynthetic bacteria are coated in the methacrylic acid-ethyl acrylate copolymer. According to the invention, not only are the problems of insufficient stability and low bioavailability of oral bacteria in vivo solved, but also intestinal-tumor immune cascade reaction and flora homeostatic reconstitution are realized through a multi-way action mechanism, and the preparation has an important clinical application prospect.

This invention provides a genetically engineered biomimetic microsphere for hydration remodeling, its preparation method, and its application, belonging to the field of biomedical technology. This invention develops an injectable composite system, GBA / SRGN@HADA@GelMA, which possesses the ability to regulate hydration and intervene in genes through interface biomimetic design and multi-level functional integration. It uses HADA as a moisturizing outer layer, provides mechanical support through GelMA microspheres, and achieves targeted delivery of SRGN siRNA through G5-GBA loading, thereby achieving synergistic regulation of the degenerative nucleus pulposus microenvironment. GBA / SRGN@HADA@GelMA reduces the expression of inflammatory factors and matrix degradation genes, and significantly promotes the accumulation of HA and lubricating proteins. This enhances the water retention capacity and interfacial lubrication of the nucleus pulposus, thereby improving compressive elasticity and energy absorption capacity. This invention is the first to combine continuous water regulation, lubrication, mechanical buffering, and extracellular matrix homeostasis regulation to synergistically delay intervertebral disc degeneration, providing an excellent treatment strategy for degenerative intervertebral disc diseases.

The present invention provides an injectable magnesium-loaded lipid-based super-lubricating hydrogel microsphere, an articular cavity injection formulation, and a preparation method therefor. The method comprises the following steps: S1, preparing a magnesium-loaded multilamellar vesicular liposome suspension containing magnesium ions; S2, preparing an uncrosslinked magnesium-containing hydrogel; and S3, mixing the magnesium-loaded multilamellar vesicular liposome suspension with the magnesium-containing hydrogel to prepare hydrogel droplets, and carrying out crosslinking to form the magnesium-loaded lipid-based super-lubricating hydrogel microspheres. According to the present invention, the magnesium loading capacity of the lipid-based super-lubricating hydrogel microspheres can be greatly improved; on one hand, the biological function provided by the magnesium ions can be greatly prolonged, that is, the repair of cartilage by synovial liquid progenitor cells is continuously promoted; and on the other hand, the intrinsic lubricating effect of the lipid-based super-lubricating hydrogel microspheres can mitigate the further wear of newly formed cartilage; in addition, the magnesium ions can significantly promote the expression of PRG4 in chondrocytes, which not only facilitates the maintenance of chondrocyte homeostasis, but also further enhances articular lubrication.

The invention belongs to the technical field of biomedicine, and relates to a novel application of 3-O-methyl chrysotoxin, in particular to an application of 3-O-methyl chrysotoxin in preparation of a medicine for treating xerophthalmia. The core of the 3-O-methyl chrysotoxin disclosed by the invention is that the 3-O-methyl chrysotoxin effectively relieves corneal epithelial cell injury induced by hyperosmosis and inhibits oxidative stress and proinflammatory factor release by activating an EGFR (Epidermal Growth Factor Receptor) signal channel. In-vitro and in-vivo experiments prove that the composition can remarkably enhance cell activity, reduce apoptosis and active oxygen accumulation and repair the steady state of a tear film. The compound is applied to preparation of xerophthalmia drugs and has important clinical value.

Disclosed is a compound of formula (I), its hydrate, anhydrous or salt form thereof, wherein M, X and n are as disclosed herein. The compounds can be used modulating activity of aryl hydrocarbon receptor (AhR), and for treatment of diseases associated with modulating AhR activity. Also disclosed are pharmaceutical compositions containing the compound of formula (I), its hydrate, anhydrous or salt form thereof. (Formula I)

The present invention discloses the use of AZA1 in the preparation of a drug for treating sepsis and the drug itself, belonging to the field of biomedicine. AZA1 of the present invention can mediate hypothalamic microglial homeostasis through the Arhgap24-Rac1 / Cdc42 signaling axis, regulating the septic immune response, thereby promoting sepsis recovery and improving prognosis, providing a potential new strategy for central nervous system immune regulation in the treatment of patients with systemic sepsis.

The invention provides application of an NLP4 gene in regulation and control of phosphorus homeostasis of rice, the nucleotide sequence of the NLP4 gene is shown as SEQ ID NO.1 in a sequence table, and the amino acid sequence of the NLP4 gene is shown as SEQ ID NO.3 in the sequence table.